Literature DB >> 18265423

Occult hepatitis B virus and hepatitis C virus infections.

Vicente Carreño1, Javier Bartolomé, Inmaculada Castillo, Juan Antonio Quiroga.   

Abstract

Occult HBV infection is a well-recognised clinical entity characterised by the detection of HBV-DNA in serum and/or in liver in the absence of detectable hepatitis B surface antigen (HBsAg). Occult HBV infection has been described not only in patients who have resolved an acute or chronic HBV infection but also in patients without any serological markers of a past HBV infection. Occult HBV infection in patients with chronic HCV infection may induce more severe liver disease and lower response rate to interferon treatment. The existence of occult HCV infections has been also reported more recently. Occult HCV infection is characterised by the presence of HCV-RNA in liver and peripheral blood mononuclear cells in the absence of detectable serum HCV-RNA. Occult HCV infection may occur under two different clinical situations: in hepatitis C antibody-(anti-HCV) negative and serum HCV-RNA-negative patients with abnormal liver function tests and in anti-HCV-positive patients who have no detectable serum HCV-RNA and who have normal liver enzymes. The clinical relevance of occult HCV infections is still under investigation. 2008 John Wiley & Sons, Ltd

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18265423     DOI: 10.1002/rmv.569

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  21 in total

1.  Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis.

Authors:  Deepak Amarapurkar; Anjali Amarapurkar
Journal:  J Clin Exp Hepatol       Date:  2015-10-23

2.  New perspectives in occult hepatitis C virus infection.

Authors:  Vicente Carreño; Javier Bartolomé; Inmaculada Castillo; Juan Antonio Quiroga
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

3.  Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy.

Authors:  Mohamed H Emara; Nahla E El-Gammal; Lamiaa A Mohamed; Maged M Bahgat
Journal:  Virol J       Date:  2010-11-17       Impact factor: 4.099

Review 4.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

5.  Hepatitis C virus lymphotropism and peculiar immunological phenotype: effects on natural history and antiviral therapy.

Authors:  Paolo Conca; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

6.  Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay.

Authors:  Philippe Halfon; Marc Bourlière; Denis Ouzan; Damien Sène; David Saadoun; Hacène Khiri; Guillaume Pénaranda; Agnes Martineau; Valérie Oulès; Patrice Cacoub
Journal:  J Clin Microbiol       Date:  2008-04-30       Impact factor: 5.948

Review 7.  Hepatitis C virus infection in nephrology patients.

Authors:  Lionel Rostaing; Jacques Izopet; Nassim Kamar
Journal:  J Nephropathol       Date:  2013-07-01

8.  Impact of hepatitis B exposure on sustained virological response rates of highly viremic chronic hepatitis C patients.

Authors:  Ioannis S Elefsiniotis; Christos Pavlidis; Elena Vezali; Theodoros Mariolis-Sapsakos; Sotirios Koutsounas; George Saroglou
Journal:  Gastroenterol Res Pract       Date:  2009-04-15       Impact factor: 2.260

9.  Occult HCV infection: an unexpected finding in a population unselected for hepatic disease.

Authors:  Laura De Marco; Anna Gillio-Tos; Valentina Fiano; Guglielmo Ronco; Vittorio Krogh; Domenico Palli; Salvatore Panico; Rosario Tumino; Paolo Vineis; Franco Merletti; Lorenzo Richiardi; Carlotta Sacerdote
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

Review 10.  Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection.

Authors:  Peiman Habibollahi; Saeid Safari; Nasser E Daryani; Seyed M Alavian
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.